{"id":925836,"date":"2026-01-09T09:35:36","date_gmt":"2026-01-09T14:35:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"modified":"2026-01-09T09:35:36","modified_gmt":"2026-01-09T14:35:36","slug":"cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BERKELEY HEIGHTS, N.J., Jan.  09, 2026  (GLOBE NEWSWIRE) &#8212; CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44<sup>th<\/sup> annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST.<\/p>\n<p align=\"justify\">\n        <strong>44th Annual J.P. Morgan Healthcare Conference<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%\">Date:<\/td>\n<td style=\"max-width:90%;width:90%;min-width:90%\">Monday, January 12, 2026<\/td>\n<\/tr>\n<tr>\n<td>Time:<\/td>\n<td>4:30pm PST<\/td>\n<\/tr>\n<tr>\n<td>Format:<\/td>\n<td>Presentation<\/td>\n<\/tr>\n<tr>\n<td>Webcast:<\/td>\n<td style=\"text-align: justify;vertical-align: middle\">\n            <a href=\"https:\/\/jpmorgan.metameetings.net\/events\/healthcare26\/sessions\/317938-cormedix-inc\/webcast?gpu_only=true&amp;kiosk=true\" rel=\"nofollow\" target=\"_blank\">Link<\/a><br \/>\n            \n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About CorMedix<\/strong>\n      <\/p>\n<p align=\"justify\">CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing <em>DefenCath<\/em><sup>\u00ae<\/sup> (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including <em>MINOCIN<\/em><sup>\u00ae<\/sup> (minocycline) for Injection, <em>REZZAYO<sup>\u00ae<\/sup><\/em>\u00a0(rezafungin for injection), <em>VABOMERE<sup>\u00ae<\/sup><\/em>\u00a0(meropenem and vaborbactam), <em>ORBACTIV<\/em>\u2122 (oritavancin), <em>BAXDELA<\/em><sup>\u00ae<\/sup> (delafloxacin), and <em>KIMYRSA<sup>\u00ae<\/sup><\/em>\u00a0(oritavancin), as well as <em>TOPROL-XL<sup>\u00ae<\/sup><\/em>\u00a0(metoprolol succinate).<\/p>\n<p align=\"justify\">CorMedix has ongoing clinical studies for <em>DefenCath<\/em> in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop <em>DefenCath<\/em> as a catheter lock solution for use in other patient populations. <em>REZZAYO<\/em> is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OKkBdCl7vq3cK939XA-6bv8oerjJ5CWSHGf_unAei_q-6z1trO4vGCpqu_7zpmGYgPo82d6Hp_R1CwRUrpNSbH8mVTkVk2ry1B9glJ7iiIudPvAlh4jsMPWJoTOaCXB20_iQXL--X2W96EoEn6w0Y6GA4QI2yyUjtOl-DP2GO5y2FHQugKGYbZn9nPe3jncp1CC3mRl68MWEk1S7MQzWpQn98Q864y_u9x19AwEUYkk=\" rel=\"nofollow\" target=\"_blank\">www.cormedix.com<\/a> or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G0spdKz4DxUZg7f6v9lx-dVNLx6HEveX5CblJMNssIQIUuRsuRg8oUJVRMOECni6DFNpArmRKk4yNNSi3oEfbg==\" rel=\"nofollow\" target=\"_blank\">www.melinta.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Dan Ferry<br \/>Managing Director<br \/>LifeSci Advisors<br \/>daniel@lifesciadvisors.com<br \/>(617) 430-7576<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTBmMDIxOWQtMGFlMy00ZDlhLWI4ZWQtMDAyYzlkYTI2OTIxLTUwMDA2NTY3OC0yMDI2LTAxLTA5LWVu\/tiny\/CorMedix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) &#8212; CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST. 44th Annual J.P. Morgan Healthcare Conference Date: Monday, January 12, 2026 Time: 4:30pm PST Format: Presentation Webcast: Link About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath\u00ae (taurolidine and heparin) for the prevention &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-925836","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) &#8212; CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST. 44th Annual J.P. Morgan Healthcare Conference Date: Monday, January 12, 2026 Time: 4:30pm PST Format: Presentation Webcast: Link About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath\u00ae (taurolidine and heparin) for the prevention &hellip; Continue reading &quot;CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-09T14:35:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2026-01-09T14:35:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":284,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==\",\"datePublished\":\"2026-01-09T14:35:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) &#8212; CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST. 44th Annual J.P. Morgan Healthcare Conference Date: Monday, January 12, 2026 Time: 4:30pm PST Format: Presentation Webcast: Link About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath\u00ae (taurolidine and heparin) for the prevention &hellip; Continue reading \"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-09T14:35:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference","datePublished":"2026-01-09T14:35:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":284,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","name":"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==","datePublished":"2026-01-09T14:35:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjc0NiM3MzUyNzIxIzUwMDA2NTY3OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cormedix-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=925836"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925836\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=925836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=925836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=925836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}